NCT03910725: EPORVA

Electrophysiological Phenotyping Of Patients at Risk of Ventricular Arrhythmia and Sudden Cardiac Death

Status unknown Last updated 25 August 2021

What this trial tests

trial testing Electrocardiographic imaging in Arrhythmia in 100 participants. Status unknown.

Timeline

21 November 2019

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Imperial College London
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	21 November 2019
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	2 locations across United Kingdom

Drugs / interventions tested

• Electrocardiographic imaging

Conditions studied

• Arrhythmia — all drugs for Arrhythmia →
• Sudden Cardiac Death — all drugs for Sudden Cardiac Death →
• Cardiomyopathy, Dilated — all drugs for Cardiomyopathy, Dilated →
• Obesity — all drugs for Obesity →

Sponsor

Imperial College London

Who can join

Adults 18 to 75, any sex, with Arrhythmia or Sudden Cardiac Death. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obesity, rheumatoid arthritis (RA) and gene-specific dilated cardiomyopathy (DCM) are common medical conditions. Small-scale studies have shown that these are associated with proarrhythmic changes on 12-lead electrocardiogram (ECG) and a higher risk of sudden cardiac death (SCD). However, these studies lack the deep electrophysiological phenotyping required to explain their observations. Electrocardiographic imaging (ECGi) is a non-invasive alternative to 12-lead ECG, by which epicardial potentials, electrograms and activation sequences can be recorded to study adverse electrophysiological modelling in greater depth and on a more focussed, subject-specific scale. Therefore, this study proposes to better define the risk of arrhythmia and understand the underlying adverse electrophysiological remodelling conferring this risk in three groups (obesity, RA and DCM). Firstly, data from two large, national repositories will be analysed to identify associations between routine clinical biomarkers and proarrhythmic 12-lead ECG parameters, to confirm adverse electrophysiological remodelling and a higher risk of arrhythmia. Secondly,ECGi will be performed before and after planned clinical intervention in obese and RA patients, and at baseline in titin-truncating variant (TTNtv)-positive and -negative DCM patients, to characterise the specific and potentially reversible conduction and repolarisation abnormalities that may underlie increased arrhythmic risk.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. The apicobasal dispersion of ventricular repolarization in humans is associated with age and affects arrhythmia vulnerability.
   Sobota V, Stoks J, Patel KHK, Shetty R, et al · · 2025 · cited 2× · PMID 40434181 · DOI 10.1113/jp288356